← All trials
NCT05629962
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Jan 31, 2024
- First posted
- Nov 29, 2022
- Last posted
- Nov 29, 2022
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Atea Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.